Compare Cytokinetics Inc (CYTK) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs NetEase Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while NetEase Inc trades at $122.45 (market cap $76.09B). The key difference: NetEase Inc is far larger — about 8.8× Cytokinetics Inc's market cap, and NetEase Inc pays a 2.45% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and NetEase Inc for 74 Days on average.
| CYTK | NTES | |
|---|---|---|
Market Cap | $8.62B | $76.09B |
Volume | 2,594,626 | 486,447 |
Sector | Health | Technology |
52-Week High | $87.26 | $152.85 |
52-Week Low | $54.76 | $109.26 |
Typical Hold Time | 19 Days | 74 Days |
Enterprise Value | $8.72B | $51.81B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
NetEase (NTES) trades at $120.61, up 1.29% with neutral technical signals and mixed earnings performance. The company maintains strong fundamentals with $112.63B revenue, 27.88% net margin, and robust cash flow. Recent Q2 2026 earnings missed expectations despite revenue growth, while analyst consensus remains strongly bullish with $168 price target representing 39% upside potential.
NTES presents compelling value with reasonable valuation multiples (P/E 16.06, EV/EBITDA 8.15) and strong profitability metrics. Key risks include earnings volatility and competitive pressures in gaming. The stock offers attractive upside based on analyst targets, supported by the company's solid balance sheet and consistent dividend growth track record.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
